Introduction
Acute leukemias represent a paradigm for understanding how genetic and epigenetic modifications lead to tumorigenesis (Figueroa et al., 2010; Rodriguez-Paredes and Esteller, 2011) . Despite the complexity of these alterations, which represent a challenge in developing targeted therapies, numerous efforts have been focused on developing effective agents for acute leukemias Dawson et al., 2011; Peloquin et al., 2013; Zuber et al., 2011) . Acute leukemias with translocations of the Mixed Lineage Leukemia gene (MLL), which constitute about 5-10% of acute leukemias in adults (Marschalek, 2011) and ~70% of acute leukemias in infants (Tomizawa et al., 2007) , still represent mostly incurable diseases (Dimartino and Cleary, 1999; Marschalek, 2011) . Fusion of MLL with one out of over 60 partner genes leads to expression of chimeric MLL fusion proteins, all of which retain an approximately 1,400 amino acids N-terminal fragment of MLL fused with the fusion partner (Hess, 2004; Krivtsov and Armstrong, 2007; Slany, 2009) . Expression of MLL fusion proteins enhances proliferation and blocks differentiation of hematopoietic cells, ultimately leading to acute leukemia (Slany, 2005) . Patients with MLL leukemias respond poorly to currently available treatments (Slany, 2005) , with only about 35% 5-year overall survival rate (Dimartino and Cleary, 1999) , emphasizing the urgent need for development of more effective therapies.
The MLL fusion proteins interact with menin, a protein that binds to the N-terminal fragment of MLL retained in all MLL fusion proteins (Caslini et al., 2007; Grembecka et al., 2010; Yokoyama and Cleary, 2008; Yokoyama et al., 2005) . Numerous studies demonstrated a critical role of menin as an oncogenic cofactor in leukemic transformations mediated by MLL fusion proteins (Caslini et al., 2007; Yokoyama and Cleary, 2008; Yokoyama et al., 2005) . Menin is a highly specific and direct binding partner of MLL and MLL fusion proteins that is required for regulation of their target genes (Yokoyama et al., 2005) . Genetic disruption of the menin-MLL fusion protein interaction abrogates oncogenic properties of MLL fusion proteins and blocks development of acute leukemia in vivo (Yokoyama et al., 2005) . These data, together with the evidence that menin is not a requisite cofactor of MLL1 during normal hematopoiesis , validate the menin-MLL interaction as an attractive therapeutic target to develop targeted drugs for MLL leukemia patients.
Despite the critical role of menin in leukemogenesis mediated by MLL fusion proteins, it remains unknown whether pharmacological inhibition of the menin-MLL interaction can suppress development of acute leukemia in vivo and whether it would affect normal hematopoiesis. We previously reported first-generation small molecule inhibitors of the menin-MLL interaction He et al., 2014; Shi et al., 2012) , which represent valuable tool compounds, but are not suitable for in vivo studies due to moderate cellular activity and poor pharmacological properties. The goal of this study was to develop highly potent small molecule inhibitors of the menin-MLL interaction with appropriate pharmacokinetic profile and to determine whether small molecule inhibition of the menin-MLL interaction can represent a valid therapeutic approach for acute leukemias associated with MLL rearrangements.
Results

Structure-based development of potent menin-MLL inhibitors
To develop menin-MLL inhibitors with favorable drug-like properties suitable for in vivo efficacy studies, we employed structure-based design and very substantially reengineered our previously reported compounds represented by the most potent MI-2-2, Figure S1A , Shi et al., 2012) . Although MI-2-2 represents a useful chemical tool, it is not suitable for in vivo efficacy studies due to modest cellular activity and very poor metabolic stability (Figure S1A-C). Using the crystal structure of the menin-MI-2-2 complex we employed structure-based design combined with medicinal chemistry efforts, resulting in development of menin-MLL inhibitors with modified molecular scaffold (Table S1 ). These efforts led to identification of MI-136 ( Figure 1A ), which was developed by introducing the cyano-indole ring connected to the thienopyrimidine core via a piperidine linker (Table S1 ). MI-136 demonstrates potent inhibitory activity and strong binding affinity to menin ( Figure 1A ), providing an excellent molecular scaffold for further modifications. Based on the binding mode of MI-136 to menin ( Figure S1D ), we explored three substitution sites on the indole ring of MI-136 (R1, R2 and R3, Figure 1B ) to further improve potency and drug-like properties by optimizing hydrophobic contacts (at R2) or polar interactions (at R1 and R3) ( Table S2 ). The molecular determinants for recognition of MI-136 analogues in the MLL binding site on menin are summarized in Figure 1B . Our medicinal chemistry efforts resulted in identification of two lead compounds: MI-463 and MI-503, which were obtained by combining two (MI-463) or three (MI-503) best substituents on the indole ring ( Figure 1C , Table S2 ). MI-503 and MI-463 are the most potent inhibitors we developed, both bind to menin with low nanomolar binding affinities, and demonstrate very potent inhibition of the menin-MLL interaction ( Figure 1C, 1D and Figure S1E ). Crystal structure validates binding of MI-503 to the MLL site on menin ( Figure 1E , Table S3 ). MI-503 occupies the F9 and P13 pockets on menin, forming a hydrogen bond with Tyr276, and also extends beyond the P13 pocket to form hydrogen bonds with Trp341 and Glu366 ( Figure 1E ). In addition to strong in vitro potency, MI-463 and MI-503 have very favorable drug-like properties, including metabolic stability ( Figure S1C ) and pharmacokinetic profile in mice (see below), which makes them very attractive candidates to evaluate the therapeutic potential of menin-MLL inhibitors in vivo.
MI-503 and MI-463 demonstrate selective and on-target activity in MLL leukemia cells
We performed a detailed characterization of MI-463 and MI-503 in MLL leukemia cells to assess their activity, selectivity and validate the mechanism of action. First, we found that both compounds can reach the target protein in mammalian cells and effectively inhibit the menin-MLL-AF9 interaction at sub-micromolar concentrations, as assessed in the coimmunoprecipitation experiment (Figure 2A ). Treatment of murine bone marrow cells (BMC) transformed with the MLL-AF9 oncogene with MI-463 and MI-503 resulted in substantial growth inhibition, with half-maximal growth inhibitory concentration (GI 50 ) values of 0.23 μM and 0.22 μM, respectively, measured after 7 days of treatment ( Figure  2B ). The cell growth inhibitory effect of MI-503 was time-dependent, with a pronounced effect achieved after 7-10 days of treatment ( Figure S2A ), which is similar to other small molecule inhibitors of epigenetic targets, including DOT1L (Bernt et al., 2011) and EZH2 (Knutson et al., 2012) . MI-463 and MI-503 were selective towards MLL-AF9 BMCs as no effect on cell growth inhibition was observed in BMCs transformed with the Hoxa9/Meis1 oncogenes (HM-2, Figure 2B ). Similarly, we observed pronounced growth suppressive activity of MI-503 and MI-463 in a panel of human MLL leukemia cell lines (GI 50 at 250 nM -570 nM range for MI-503), but only a minimal effect in human leukemia cell lines without MLL translocations ( Figure 2C and Figure S2B ). Selective killing of MLL leukemia cells is attributed to inhibition of the menin-MLL interaction as the close analogs MI-372 and MI-405, which are much weaker menin-MLL inhibitors (IC 50 = 0.92 μM and 15.6 μM, respectively), did not show growth suppressive effects in MLL leukemia cells ( Figure S2C -S2F).
MI-503 and MI-463 were also very effective in inducing differentiation of MLL leukemia cells, as reflected by pronounced phenotypic changes from primitive blasts to more mature myeloid cells, and substantially increased expression of CD11b, a myeloid differentiation marker ( Figure 2D -2F and Figure S2G -S2I). These effects were accompanied by reduced ckit (CD117) expression, a marker associated with leukemia stem cells (LSCs) (Krivtsov et al., 2006; Somervaille and Cleary, 2006) (Figure S2J-S2K) . Interestingly, effects on apoptosis were less pronounced as higher concentrations of both compounds were required for pronounced apoptotic effect in MLL leukemia cells ( Figure 2G ). Treatment with submicromolar concentrations of MI-503 and MI-463 also led to markedly reduced expression of Hoxa9 and Meis1, downstream targets of MLL fusion proteins substantially upregulated in MLL leukemias ( Figure 2H ). Overall, we developed very potent menin-MLL inhibitors, which selectively block proliferation of MLL leukemia cells through a specific, on-target mechanism of action, representing very promising candidates for in vivo studies.
To assess the effect of a long-term treatment combined with compound withdrawal we treated MV4;11 human leukemia cells expressing MLL-AF4 with MI-503 followed by the wash-out phase to eliminate the compound and subsequent resupply with MI-503, with each phase continuing for 10 days ( Figure 2I and Figure S2L ). To avoid cell death, MI-503 was used at 0.2 -0.6 μM concentrations that inhibit proliferation but do not induce high level apoptosis. As expected, MI-503 induced marked anti-proliferative effects in the first treatment phase, with a GI 50 value of 200 nM at day 10 ( Figure 2I ). Withdrawal of MI-503 restored proliferation of MV4;11 cells; however, this effect was concentration-dependent, and less pronounced recovery was observed for cells treated with the highest MI-503 concentration ( Figure 2I ). Restoration of MI-503 treatment at day 21 resulted in further inhibition of MV4;11 cell proliferation ( Figure 2I and Figure S2L ). Interestingly, upon prolonged treatment with 0.6 μM of MI-503 the MV4;11 cells began exhausting their proliferative potential ( Figure S2L , bottom panel). Furthermore, expression of HOXA9 and MEIS1 was markedly reduced at the end of each treatment phase (days 10 and 30), ( Figure  2J ). In contrast, expression of HOXA9 and MEIS1 was restored to the DMSO control level at the end of the wash-out phase (day 20), ( Figure 2J ). These data support the need for continuous inhibition of menin to block the activity of MLL fusion oncogenes. The ability to suppress proliferation of MV4;11 cells using prolonged treatment with MI-503 suggests that resistance did not develop over the duration of the experiment.
Menin-MLL inhibitors reverse gene expression signatures associated with MLL-rearranged leukemia cells
To assess the effects of menin-MLL inhibitors on global gene expression in the MLLrearranged leukemias, we performed gene expression studies in MV4;11 human leukemia cells (expressing MLL-AF4) after treatment with the MI-389 menin-MLL inhibitor, a close analog of MI-503 with a similar in vitro and cellular activity ( Figure S3A -S3B). Significant changes in gene expression were found for 478 and 477 genes up-and downregulated, respectively (Table S4) . Gene set enrichment analysis (GSEA) demonstrated strong downregulation of genes identified as downstream targets of MLL-AF4 (Guenther et al., 2008) and MLL-AF9 (Bernt et al., 2011) following treatment with MI-389 ( Figure 3A , 3B). These included multiple genes implicated in MLL fusion protein mediated leukemogenesis, such as homeobox genes (HOXA9, HOXA10, MEIS1, PBX3), FLT3 and other downstream targets of MLL fusion proteins (MEF2C, BCL2 and CDK6) ( Figure 3A , 3B and Table S4 ). Downregulated expression of these genes was consistent with phenotypic consequences of treatment with the menin-MLL inhibitor ( Figure S3C ). GSEA also revealed a global upregulation of genes underexpressed in leukemia stem cells (CD34 + CD38 − progenitor cells) (Gal et al., 2006) and in primitive hematopoietic progenitor cells (Jaatinen et al., 2006) , including genes associated with differentiation (ITGAM, which encodes the cell surface marker CD11b associated with myeloid differentiation, and MNDA), following MI-389 treatment, Figure 3C .
We have further used qRT-PCR to validate expression changes for selected genes in MV4;11 and MOLM-13 (expressing MLL-AF9) human leukemia cell lines upon treatment with MI-389 and MI-503 ( Figure 3D , 3E). We observed markedly downregulated expression of Homeobox genes (HOXA9, HOXA10, HOXA7, PBX3, MEIS1) and other downstream targets of MLL fusion proteins (DLX2, MEF2C, FLT3) and up-regulation of MNDA, a differentiation marker of myeloid cells ( Figure 3D , 3E), consistent with the gene expression data from the microarray studies in MV4;11 cells ( Figure 3A , 3B). Overall, these results demonstrate that pharmacologic inhibition of the menin-MLL interaction reverses the gene expression signature in MLL-rearranged leukemia cells, providing an attractive strategy to reprogram these cells towards differentiation.
Menin-MLL inhibitors block hematologic tumors in vivo and reduce MLL leukemia tumor burden
We next aimed to establish the therapeutic potential of menin-MLL inhibitors in vivo using mouse models of MLL leukemia. First, we characterized the pharmacokinetic (PK) properties of MI-503 and MI-463 in mice. Both compounds achieved high level in peripheral blood following a single intravenous or oral dose, while also showing high oral bioavailability (~45% for MI-463 and 75% for MI-503), Figure 4A and Figure S4A . We then assessed the effect of MI-463 and MI-503 on in vivo tumor growth in mouse xenograft model utilizing MV4;11 human MLL leukemia cells implanted into BALB/c nude mice. Both MI-463 and MI-503 induced strong inhibition of tumor growth with once daily intraperitoneal (i.p.) administration, albeit MI-503 showed more pronounced effects ( Figure  4B ). Treatment with MI-503 resulted in an over 80% reduction in MV4;11 tumor volume and complete tumor regression in two mice. Pronounced tumor growth inhibition correlated well with the level of both compounds in the tumor samples ( Figure S4B ). Importantly, prolonged treatment (38 days) with MI-503 induced no toxicity in mice as reflected by no alterations in the body weight and no morphological changes in liver and kidney tissues ( Figure S4C , S4D). Furthermore, gene expression studies performed in samples isolated from the MV4;11 tumors revealed significant reduction in expression of MLL fusion protein target genes, HOXA9 and MEIS1, upon treatment with MI-503 and MI-463 ( Figure 4C ). Taken together, the reduction in tumor growth correlated with a decrease in expression of MLL-fusion target genes in vivo, validating on-target activities of MI-463 and MI-503.
We then assessed the effect of MI-503 and MI-463 in disseminated human MLL-AF4 leukemia using a xenotransplantation model. MV4;11 cells expressing luciferase were injected into NSGS or NSG mice via tail vein and treatment was initiated 5 days later to allow for efficient engraftment of leukemic cells. Leukemia progression was monitored by bioluminescence imaging. Based on the pharmacokinetic profiles, we selected twice-daily treatment regimen to sustain a therapeutic concentration of the compounds in the blood. Ten consecutive days of treatment with MI-503 resulted in a marked delay in progression of MLL leukemia in mice and significantly reduced leukemia tumor burden ( Figure 4D and Figure S4E ). Similarly, 20 days treatment of MV4;11 xenograft recipient mice with MI-463 also resulted in a substantial delay in leukemia progression as manifested by a marked decrease in the bioluminescence level measured over the course of the experiment ( Figure  4E , 4F). Reduced bioluminescence was associated with a significant decrease in the population of leukemic cells in the peripheral blood, spleen and bone marrow samples harvested from mice treated with MI-463 ( Figure 4G ). Furthermore, we observed reduced expression of MLL fusion target genes (HOXA9, MEIS1, MEF2C) and increase in the expression level of ITGAM upon treatment of mice with MI-463 ( Figure 4H ). Collectively, these findings demonstrate that MI-503 and MI-463 have a potent anti-leukemic effect in vivo when applied as single agents. Importantly, these data suggest that resistance did not emerge after prolonged (20 days) treatment with MI-463.
Menin-MLL inhibitors substantially improve survival of MLL leukemic mice
We next assessed the effects of menin-MLL inhibitors on survival of MLL leukemia mice, using a bone marrow transplantation model of murine MLL-AF9 leukemia ( Figure S5A ). Despite short latency time in this aggressive leukemia model (~15 days) we initiated treatment five days after transplantation to test efficacy of menin-MLL inhibitors in the established disease model. MI-463 at 50 mg/kg and MI-503 at 80 mg/kg were administered twice daily by oral gavage for ten consecutive days. The presence of abundant blasts in the peripheral blood, bone marrow and spleen was used to validate terminal leukemia in mice ( Figure S5B ). Importantly, treatment with either compound strongly delayed leukemia progression as reflected by a substantial survival benefit in MLL-AF9 leukemia mice when MI-463 and MI-503 were applied as single agents ( Figure 5A ). The median survival of MLL-AF9 leukemia mice was increased by ~70% and ~45% upon treatment with MI-463 and MI-503, respectively ( Figure 5A ), demonstrating their pronounced effects in blocking MLL leukemia progression in vivo.
To further validate that treatment with menin-MLL inhibitors delayed leukemia progression, we additionally tested the MI-463 compound in the MLL-AF9 leukemia model using the same treatment regimen as in survival experiment ( Figure 5A ). Following 10 days of treatment all animals were sacrificed and extensive analysis of leukemia progression was performed in vehicle and compound treated cohorts with samples collected at the same time point. We observed notably reduced spleen size and weight ( Figure 5B and 5C) and substantially decreased level of blasts in bone marrow samples upon treatment with MI-463 versus vehicle control ( Figure 5D and 5E). These effects were accompanied by substantially reduced blast infiltration of the liver and spleen upon treatment with MI-463 ( Figure 5F and Figure S5C ). The bone marrow samples isolated from mice treated with MI-463 showed a sub-population of cells with a differentiated phenotype as manifested by the appearance of cells with a neutrophil-like morphology ( Figure 5G ). The white blood cell count was decreased in the peripheral blood of the MLL-AF9 mice upon treatment with MI-463, while other blood cells and blood parameters were not affected ( Figure 5H and Figure S5D ). MI-463 administration was well tolerated, and no significant body weight loss was observed ( Figure S5E ). Furthermore, treatment of mice with MI-463 resulted in a marked reduction in the expression level of MLL-fusion downstream targets, Hox9, Meis1, Mef2c and Flt3, as well as a substantial increase in the expression level of Itgam differentiation marker in the bone marrow samples ( Figure 5I ). Taken together, these data demonstrate that pharmacologic inhibition of the menin-MLL interaction substantially delays progression of MLL leukemia in vivo in murine models through on-target activity without causing toxicity.
Menin-MLL inhibitors do not impair normal hematopoiesis in vivo
Given the role of MLL1 in normal hematopoiesis (Ernst et al., 2002; McMahon et al., 2007) , we assessed whether pharmacological inhibition of the menin-MLL interaction affects the normal hematopoiesis in mice. C57BL/6 mice were treated with efficacious doses of MI-463 and MI-503 for 10 days using the same treatment regimen as in survival experiments ( Figure  5A ). Importantly, no decrease in body weight, organ weight or tissue damage was observed upon treatment with either compound (Figure S6A-S6C) . We then performed detailed analysis of bone marrow samples and found that bone marrow cellularity was preserved upon treatment with MI-463 and MI-503 ( Figure 6A ). Flow cytometric analysis showed that bone marrow cell populations highly enriched for hematopoietic stem cells were not decreased upon treatment with menin-MLL inhibitors (LSK progenitors defined as Lin − Sca-1 + c-Kit + and long-term hematopoietic stem cells defined as LSK CD48 − CD150 + ) ( Figure 6B ). In fact these populations were even slightly increased upon treatment. Analysis of mature myeloid cells (CD11b + Gr-1 + ) showed no impact in the inhibitor-treated mice ( Figure 6C ). Phenotypic analysis of B cell populations showed a mild increase in pro-B cell numbers and no effect on other B cells populations upon treatment with MI-463 and MI-503 ( Figure 6D and Figure S6D ). Gene expression analysis performed in LSK progenitors showed no reduction in the expression level of the menin and/or MLL dependent genes, including Hoxa9 and Meis1, upon treatment of mice with MI-463 or MI-503 ( Figure 6E and Figure S6E ). This is consistent with the modest effect on expression of these genes reported in LSKs after genetic loss of Men1 encoding menin (Artinger et al., 2013; Li et al., 2013; ). These results suggest that the MLL-rearranged cells are more sensitive to the treatment with the menin-MLL inhibitors than normal LSKs, supporting the existence of a therapeutic window for these compounds.
We have also assessed the effect of MI-503 on normal hematopoiesis after prolonged treatment of mice (38 days of continued treatment with efficacious doses of MI-503) using the xenograft MV4;11 model described above ( Figure 4B ). No significant effect on bone marrow cellularity, Lin − c-Kit + progenitors and long-term hematopoietic stem cells was observed ( Figure 6F-6G) , with a slight increase in mature myeloid cells in bone marrow ( Figure 6F ). Overall, these findings show that pharmacologic inhibition of the menin-MLL interaction dose not negatively affect normal hematopoiesis, which rules out a potential "ontarget" toxicity of the menin-MLL inhibitors. Importantly, our results are in agreement with recent studies suggesting that menin is not a requisite cofactor of MLL1 during normal hematopoiesis Maillard and Hess, 2009 ).
Menin-MLL inhibitors selectively kill MLL leukemia primary patient samples
To evaluate therapeutic potential of menin-MLL inhibitors we studied the effects of MI-503 and MI-463 on primary samples isolated from MLL leukemia patients as well as in several AML patient samples without MLL translocation ( Figure S7A, S7B ). Both compounds substantially reduced clonogenic efficiency in all MLL leukemia patient samples, with over 50% reduction in colony number at submicromolar or low micromolar concentrations ( Figure 7A) . Notably, the morphology and size of colonies changed upon treatment with menin-MLL inhibitors, resulting in significantly smaller and more diffuse colonies when compared to DMSO treated samples ( Figure 7C ). In contrast, both compounds had little effect on colony formation in control AML patient samples, except at the highest concentration (6 μM) in the AML-9571 sample ( Figure 7B and 7C).
We also assessed the effect of MI-463 in an additional set of AML patient samples and observed a marked decrease in cell growth and blast population in MLL leukemia patient samples but not in primary AML samples without MLL translocations ( Figure 7D , 7E and Figure S7C-S7D) . Furthermore, increased cell size was observed following treatment with MI-463 specifically in primary MLL leukemia cells but not in other AML samples ( Figure  7E ), suggesting differentiation of these cells, although this effect needs further investigation. No effect on growth and blast population in the primary MLL patient samples was detected for MI-372 negative control compound ( Figure S7C-S7E) . Taken together, these data provide compelling evidence supporting the therapeutic potential of menin-MLL inhibitors in MLL leukemias.
Discussion
Acute leukemias with MLL rearrangements represent an unmet medical need as therapeutic agents have not been developed for clinical use in MLL leukemia patients. Menin plays a critical role as an oncogenic co-factor of MLL fusion proteins in leukemia (Yokoyama et al., 2005) . Based on genetic data, inhibition of the menin-MLL interaction was proposed as a potential therapeutic approach Yokoyama et al., 2005) , but this strategy has not been validated with pharmacologic agents. Here, we demonstrate that pharmacologic inhibition of the menin-MLL interaction with small molecules blocks progression of MLL leukemia in vivo without impairing normal hematopoiesis. These effects were achieved with small molecule inhibitors MI-463 and MI-503 that directly bind to menin with low nanomolar binding affinities and effectively block the menin-MLL interaction. Both compounds have appropriate pharmacokinetic profile and high oral bioavailability and their in vivo administration results in a substantial extension of survival in a mouse model of MLL leukemia through on-target mechanism of action. Importantly, these compounds do not impair normal hematopoiesis in mice, providing evidence that a sufficient therapeutic window can be achieved. Overall, this study supports clinical applications of menin-MLL inhibitors as targeted therapeutics against MLL-rearranged leukemias.
Based on our studies, MI-463 and MI-503 are two lead compounds with comparable efficacy and drug-like properties. MI-503 has better oral bioavailability and can be tolerated at higher doses in mice, but at this point we cannot distinguish which compound might represent a better candidate for further development as targeted therapy for the treatment of patients suffering from MLL leukemia. Follow-up studies, including pharmacological formulation, pharmacokinetic studies and long term toxicity in other species, including rats and dogs, are required to address this question. In case any potential undesired side effects emerge, additional substitutions on the indole ring of MI-463 or MI-503 could be explored to modulate these properties.
In this study we provide an example of targeted drug discovery where the oncogenic effects of genetic alterations can be reversed by effective blocking of a protein-protein interaction critical for oncogenesis. This approach represents an attractive strategy to develop therapies, as protein-protein interactions typically show a high level of evolutionary conservation and functional mutations leading to drug resistance are far less likely to occur than in enzymes. These considerations, together with the results of our studies, validate that in vivo pharmacological inhibition of the menin-MLL fusion protein interaction offers a promising therapeutic opportunity for acute leukemias with MLL rearrangements. Recent reports emphasize oncogenic role of menin in other cancers, including hepatocellular carcinomas (Xu et al., 2013) , raising a possibility that pharmacologic inhibition of this protein-protein interaction might have broader therapeutic applications in oncology, both for hematologic malignancies and solid tumors. The two compounds we report here may represent clinical lead candidates or provide an advanced molecular scaffold for further optimization into clinical lead compounds.
Experimental Procedures Chemistry
Chemical synthesis and chemical characterization of compounds are provided in the Supplemental Experimental Procedures.
Biochemical, biophysical and structural characterization of menin-MLL inhibitors
Inhibition of the menin-MLL interaction by small molecules was assessed by fluorescence polarization (FP) assay using the protocol described previously (Grembecka et al., 2010; Grembecka et al., 2012) . Binding affinity of compounds (MI-136, MI-389, MI-463 and MI-503) to menin was assessed using Isothermal Titration Calorimetry experiments performed at 25 °C with compounds (50 μM -100 μM) injected into menin (5 μM -10 μM) in 10 μl aliquots. For co-crystallization experiments 2.5 mg/mL menin was incubated with small molecule inhibitors (MI-136 or MI-503) at 1:3 molar ratio. Crystals were obtained using the sitting drop technique at 10 °C by applying the procedure described previously . More details can be obtained in Supplemental Experimental Procedures.
Viability assays, cell differentiation and gene expression studies
For viability assays, leukemia cells were plated at relevant concentrations and treated with compounds or 0.25% DMSO and cultured at 37 °C for 7 days. Media was changed at day 4, viable cell numbers were restored to the original concentration and compounds were resupplied. MTT cell proliferation assay kit (Roche) was then employed, and plates were read for absorbance at 570 nm using a PHERAstar BMG microplate reader. Effect of menin-MLL inhibitors on expression level was assessed by Real-time quantitative PCR (qRT-PCR) after 6 days of incubation of compounds with cells, with media changed and compound resupply at day 3. For cell differentiation studies, leukemia cells were treated with menin-MLL inhibitors for 7 days, then harvested, washed and incubated with Pacific Blue rat antimouse CD11b antibody (BD BioLegend, cat # 101224) before being analyzed by flow cytometry. More details can be obtained in Supplemental Experimental Procedures.
Efficacy studies in mice
All animal experiments were approved by the University of Michigan Committee on Use and Care of Animals and Unit for Laboratory Animal Medicine (ULAM). For efficacy studies in MV4;11 subcutaneous xenograft mice model, 5 × 10 6 cells were injected into the 4-6 week old female BALB/c nude mice. Treatment was started when the tumor size reached ~100 mm 3 . Vehicle (25% DMSO, 25% PEG400, 50% PBS) or compounds (MI-463 or MI-503) were administrated once daily at designated doses using i.p. injections. For mice efficacy studies in bioimaging MV4;11 xenograft model, 6 to 8-week-old female NSGS or NSG mice were intravenously injected with 1 × 10 7 or 0.5 × 10 7 luciferase-expressing MV4;11 cells. At day 5, treatment with compound of vehicle was initiated and continued for 10-20 consecutive days. To generate the MLL-AF9 leukemic mice, C57BL/6 female mice were transplanted with 1 × 10 5 spleen or bone marrow cells isolated from the primary recipient mice. Five days post-transplantation treatment with MI-463, MI-503 or vehicle was initiated and continued for 10 days. Mice were sacrificed upon signs of disease. Leukemia was confirmed by flow cytometric analysis of GFP + cells as a surrogate for MLL-AF9 expression. More details can be obtained in Supplemental Experimental Procedures.
Analysis of normal hematopoiesis in mice
Normal hematopoiesis was studies in C57BL/6 mice after 10 days of treatment with MI-463, MI-503 or vehicle control and in the BALB/c nude mice after 38 days of treatment with MI-503. See Supplemental Experimental Procedures for more details.
Primary patient samples
Patient-derived AML samples were collected in accordance with the guidelines and approval of institutional review boards at University of Pennsylvania Hospital, Weill Cornell Medical College, New York Presbyterian Hospital, and University of Michigan Hospital, and informed consent of each patient. Peripheral blood samples were collected and processed to isolate mononuclear cells using density gradient centrifugation and red blood cell lysis. Cells were frozen in 10% DMSO until used in experiments.
Clonogenic assay in methylcellulose with primary patient samples
Primary patient samples were grown in RPMI-1640 media (Lifetechnologies), supplemented with 10% FBS and 1% penicillin/streptomycin, in the presence of 10 ng/mL human IL-3, 10 ng/mL IL-6 and 50 ng/m LSCF (PeproTech). 24 hr later, cells were plated in duplicates on methylcellulose media supplemented with human cytokines (Methocult H4435, StemCell Technologies) with cell density of 7.5-15 × 10 4 cells. Compounds or DMSO were added to the methylcellulose and incubated at 37 °C, 5% CO 2 for 14 days at which time colonies were stained with iodonitrotetrazolium chloride and counted.
Cell viability assay in primary patient samples
Primary AML samples were treated with the compounds or vehicle (0.25% DMSO) for 7 days. Cells were collected and stained with mouse anti-human CD45-APC-H7 (BD Bioscience), CD34-APC and CD38-PE-Cy7 (eBiosciences) prior to Annexin V (BD Bioscience) and 7-AAD (Life Technologies) staining. Cells were then analyzed using an LSR II flow cytometer (BD Bioscience) collecting at least 2 × 10 5 events for each sample. Data analysis was performed using FlowJo 9.3.2 software for Mac OS X (TreeStar).
Annexin V and 7-AAD double negative cells were scored as viable, and the viability was represented as the percent relative to DMSO treated cells.
Statistical analysis
Student's t-test (unpaired, two-tailed) was used to calculate significance level between treatment groups in all experiments besides survival curves, where Log-rank (Mantel-Cox) test was applied to calculate p values. P values of less than 0.05 were considered significant. Graph generation and statistical analysis were performed using GraphPad Prism version 6.02 software (GraphPad, La Jolla, CA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Significance
Chromosomal translocations of MLL occur in aggressive acute leukemias affecting both children and adults. MLL fusion proteins require menin for leukemogenic activity, and selective targeting of the menin-MLL interaction represents a potential therapeutic approach for acute leukemias with MLL rearrangements. Here, we report development of very potent and orally bioavailable small molecule inhibitors of the menin-MLL interaction, MI-463 and MI-503, which effectively block progression of MLL leukemia in vitro and in vivo, without affecting normal hematopoiesis. We also demonstrate efficacy of these compounds in primary leukemia samples derived from MLL leukemia patients. These studies provide a rationale for clinical evaluation of the menin-MLL inhibitors as a valuable therapeutic approach for acute leukemias associated with MLL rearrangements.
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